As the most exhaustive meta-analysis to investigate the efficacy of PI3K inhibitors in HR+ breast cancer according to PIK3CA mutation status, our results demonstrate that the responsive and survival outcomes of PI3K inhibitors can be significantly improved in PIK3CA-mutated population comparing with wild-type PIK3CA population. This evidence concerns the gene PIK3CB and breast carcinoma.